🩸Facts about Diffuse Large B-Cell Lymphoma:
Metabolic tumor volume, circulating tumor DNA, molecular residual disease, pola-R-CHP, and POLARIX trial outcomes.
#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
🩸Facts about Diffuse Large B-Cell Lymphoma: Metabolic tumor volume, circulating tumor DNA, molecular residual disease, pola-R-CHP, and POLARIX trial outcomes. #DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
0 vue
Publié le 18/08/2026 04:39
🩸Facts about Diffuse Large B-Cell Lymphoma:
Metabolic tumor volume, circulating tumor DNA, molecular residual disease, pola-R-CHP, and POLARIX trial outcomes.
#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
1 commentaire
?
POLARIX bought PFS without a clear OS separation, so pola-R-CHP is about who benefits rather than replacing R-CHOP outright. ctDNA is the piece most likely to change how this gets used mid-treatment. These factors sit better as a map than a list, which is what our mind maps are for.